









Markets
/
Stocks
/
nasdaq-drug
/

Bright Minds Biosciences Inc

DRUG

50.145USD

+5.465+12.23%

Close 09/18, 16:00（ET）Quotes delayed by 15 min

355.26MMarket Cap

LossP/E TTM



Bright Minds Biosciences Inc

50.145

+5.465+12.23%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated：2025-09-18

Key Insights

Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

163 / 506

Overall Ranking

282 / 4721

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 7 analysts

Buy

Current Rating

81.000

Target Price

+81.29%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Bright Minds Biosciences Inc. is a biotechnology company, which is engaged in developing treatments for patients with neurological and psychiatric disorders. The Company is focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders. Its Serotonin (5-HT) is a neurotransmitter in the brain and modulates many biological functions. Dysfunction of serotonin receptors, transporters, and associated neurocircuits is fundamental to many diseases including epilepsies and neuro psychiatric. Its pipeline includes BMB-101, BMB-xxx, BMB-201, and BMB-202. The Company has a portfolio of patented, selective serotonin (5-HT2C, 5-HT2A and 5-HT2C/A-receptor subtypes) agonists that were identified by using high-throughput screening methods in combination with advanced molecular modeling techniques to interrogate the interaction between the drug and its targeted receptors to increase downstream signaling.

Fairly Valued

The company’s latest PE is -36.39, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 6.93M shares, increasing 3.52% quarter-over-quarter.

Financial Health

Currency: USD Updated：2025-09-18

There is no financial score for this company; the Biotechnology & Medical Research industry's average is 6.93.

Score

Industry at a Glance

Previous score

0.00

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated：2025-09-18

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -32.42, which is 6.82% below the recent high of -34.63 and -389.36% above the recent low of -158.65.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 163/506

No Data

Earnings Forecast

Currency: USD Updated：2025-09-18

The company’s current earnings forecast score is 8.57, which is higher than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Bright Minds Biosciences Inc is 80.00, with a high of 93.00 and a low of 72.00.

Score

Industry at a Glance

Previous score

8.57

Change

Support & Resistance

No Data

Analyst Rating

Based on 7 analysts

Buy

Current Rating

81.000

Target Price

+81.29%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Bright Minds Biosciences Inc

DRUG

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

Ionis Pharmaceuticals Inc

IONS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated：2025-09-18

The company’s current price momentum score is 9.08, which is higher than the Biotechnology & Medical Research industry's average of 6.32. Sideways: Currently, the stock price is trading between the resistance level at 50.11 and the support level at 38.62, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.08

Change

0.58

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(2)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.308

Buy

RSI(14)

64.287

Neutral

STOCH(KDJ)(9,3,3)

74.276

Neutral

ATR(14)

3.540

Low Volatility

CCI(14)

107.710

Buy

Williams %R

11.993

Overbought

TRIX(12,20)

0.812

Sell

StochRSI(14)

83.074

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

47.533

Buy

MA10

45.659

Buy

MA20

44.003

Buy

MA50

37.838

Buy

MA100

33.368

Buy

MA200

34.925

Buy

Institutional Confidence

Currency: USD Updated：2025-09-18

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Janus Henderson Investors

1.11M

+54.45%

Cormorant Asset Management, LP

1.06M

McDonald (Ian)

1.00M

Sio Capital Management, LLC

507.56K

+12.34%

Commodore Capital LP

500.00K

Kozikowski Alan P

480.50K

+19.98%

Perceptive Advisors LLC

444.65K

+10.16%

Vivo Capital, LLC

251.57K

Adage Capital Management, L.P.

200.00K

+50.94%

Risk Assessment

Currency: USD Updated：2025-09-18

The company’s current risk assessment score is 3.18, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is -0.34. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.